5 November 2026 – Amaroq Ltd. (LSE and Nasdaq Iceland: AMRQ, OTCQX: AMRQF), an independent mine development company focused on unlocking Greenland’s mineral potential, will publish its Q3 2026 Results
Avacta to present AVA6207 at Barcelona cancer conference
Avacta Therapeutics (AIM: AVCT) has announced plans to present its next-generation dual-payload cancer drug candidate AVA6207 at the 2026 EORTC-NCI-AACR Symposium in Barcelona, highlighting a new approach designed to overcome
Amaroq – Episode 7: String of Pearls
In 2026, the conversation about Western critical mineral supply moved from strategy papers to the ground. Amaroq sits at the heart of that conversation, and in West Greenland, the company
Amaroq reports zinc grades up to 62.2% at Maarmorilik as Greenland mining strategy advances
Amaroq Ltd (LON: AMRQ; Nasdaq Iceland: AMRQ; OTCQX: AMRQF) has reported high-grade zinc, lead and silver exploration results from its Maarmorilik project in West Greenland, including samples containing up to
Avacta reports 11.4-month progression-free survival with AVA6000 in salivary gland cancer trial
Avacta Therapeutics (AIM: AVCT) has reported encouraging clinical results from its ongoing Phase 1a/1b trial of faridoxorubicin (AVA6000), with median progression-free survival reaching 11.4 months in a selected group of
Avacta reports promising AVA6103 cancer trial progress with tumour responses in Enhertu-resistant models
Avacta Therapeutics (AIM: AVCT) has reported encouraging preclinical results for its experimental cancer treatment AVA6103, demonstrating tumour responses in models resistant to Enhertu, as the company advances its Phase 1
Avacta to present cancer trial survival data and AVA6103 study design at ESMO 2026
Avacta Therapeutics (AIM: AVCT) will present updated clinical data from its Faridoxorubicin (AVA6000) cancer programme and details of its AVA6103 trial at the European Society for Medical Oncology (ESMO) Congress
Amaroq Hits 12,000oz Gold Target Early as FTSE 250 Inclusion Confirmed
Amaroq Ltd. (LON, Nasdaq Iceland: AMRQ; OTCQX: AMRQF) produced 12,000 ounces of gold during the third quarter of 2026, demonstrating a significant increase in output from its Nalunaq mine in
Avacta Therapeutics Raises £12.5m as Trading Resumes After Capital Access Window
Avacta Therapeutics (AIM: AVCT) has conditionally raised £12.5 million gross through a placing and director subscription priced at 68p per share.
Avacta Therapeutics Seeks £12.5m to Extend Cash Runway Into Q2 2027
Avacta Therapeutics (AIM: AVCT) has launched an accelerated bookbuild and subscription seeking minimum gross proceeds of approximately £12.5 million.
Avacta Opens Capital Access Window Ahead of Equity Fundraise
Avacta (AIM: AVCT) currently expects its existing cash resources to last into early Q1 2027 and is continuing discussions with potential partners for its next-generation assets.
Avacta Group Further Demonstration of Potential of AVA6103
Avacta Therapeutics (AIM: AVCT) has presented the design of its Phase 1 FOCUS-01 trial and updated preclinical data supporting AVA6103 in pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic